Phathom Pharmaceuticals, Inc.

Unity Biotechnology, a biotech firm developing drugs that eliminate or modulate senescent cells to treat diseases of aging, has been making the case for its approach in retinal diseases for the last f

Sebela’s potassium-competitive acid blocker (P-CAB) tegoprazan demonstrated superior efficacy to a proton pump inhibitor (PPI) in a Phase III trial in patients with gastroesophageal reflux disease (GE

The pace of new biopharmaceutical financings has slowed as summer enters the last sleepy weeks of August, but the handful of recent significant funding announcements have been quite large, including

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. OcuMension Signs Stock-for-Rights